**Sjögren’s syndrome**

Chair: Prof Wan Fai-Ng, University of Newcastle, Newcastle-upon-Tyne

**Aim:** To educate and update the audience on the systemic nature of Sjögren’s syndrome and the science underlying the disease and its treatment

**Outcome 1:** Appreciate that Sjögren’s syndrome is a systemic disease

**Outcome 2:** Understand the underlying immunology

**Outcome 3:** Understand the rationale for new treatments

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Systemic manifestations of Sjögren’s syndrome</td>
</tr>
<tr>
<td></td>
<td>Dr Elizabeth Price, Great Western Hospital, Swindon</td>
</tr>
<tr>
<td>09.30</td>
<td>The science behind the disease</td>
</tr>
<tr>
<td></td>
<td>Dr Francesca Barone, University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>10.00</td>
<td>Future therapeutic approaches</td>
</tr>
<tr>
<td></td>
<td>Dr Michele Bombardieri, Queen Mary University of London, London</td>
</tr>
</tbody>
</table>

---

**Rheumatoid arthritis challenges in the biologic era**

Chair: Dr Emmanuel George, Arrowe Park Hospital, Wirral

**Aim:** To understand the challenges that biologic therapy has caused

**Outcome 1:** To recognise the changes of behaviour occasioned by and necessary for biologic use in rheumatoid arthritis

**Outcome 2:** To understand factors affecting order and strategy of biologic use

**Outcome 3:** To understand the justifications needed by purchasers to fund biologic therapies

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Challenge 1: changing behaviour</td>
</tr>
<tr>
<td></td>
<td>Dr David Walker, Freeman Hospital, Newcastle-upon-Tyne</td>
</tr>
<tr>
<td>09.25</td>
<td>Challenge 2: defining strategy: different practices across devolved nations</td>
</tr>
<tr>
<td></td>
<td>Dr David Marshall, Inverclyde Royal Hospital, Greenock</td>
</tr>
<tr>
<td>09.50</td>
<td>Challenge 3: justifying use</td>
</tr>
<tr>
<td></td>
<td>Dr David Coady, Sunderland Royal Hospital, Sunderland</td>
</tr>
<tr>
<td>10.15</td>
<td>Challenge 4: defining strategy for use of biologics</td>
</tr>
<tr>
<td></td>
<td>Prof Peter Taylor, University of Oxford, Oxford</td>
</tr>
</tbody>
</table>

---

**Collaborative management of rheumatoid arthritis: how can GPs and rheumatologists help each other?**

Chairs: Dr Peter Lanyon, Nottingham University Hospital, Nottingham and Dr Louise Warburton, Primary Care Rheumatology Society

**Aim:** To inform delegates of areas of rheumatoid arthritis management which bridge rheumatology and primary care and provide opportunities for collaborative working

**Outcome 1:** Delegates will have better awareness of what the Quality and Outcomes Framework (QOF) for rheumatoid arthritis involves and how rheumatologists can help GPs

**Outcome 2:** Delegates will have a better understanding of how cardiovascular risk is assessed and treated in primary care and how this can be extended to patients with rheumatoid arthritis

**Outcome 3:** Delegates will learn how rheumatologists and GPs are working together to provide services for rheumatoid arthritis in primary care

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>The Quality and Outcomes Framework (QOF) for rheumatoid arthritis: what do GPs need from rheumatologists?</td>
</tr>
<tr>
<td></td>
<td>Dr Alan Nye, Pennine MSK Partnership Ltd, Oldham</td>
</tr>
<tr>
<td>09.30</td>
<td>Assessing cardiovascular risk in rheumatoid arthritis: a job for the GP or rheumatologist?</td>
</tr>
<tr>
<td></td>
<td>Dr Nicola Goodson, University Hospital Aintree, Liverpool</td>
</tr>
<tr>
<td>10.00</td>
<td>Doing things differently: managing rheumatoid arthritis in primary care</td>
</tr>
<tr>
<td></td>
<td>Prof Karim Raza, University of Birmingham, Birmingham and Dr Ben Empson, Vitality Community Rheumatology Service, Birmingham</td>
</tr>
</tbody>
</table>
### International challenges in rheumatology

**Chair:** Prof Jacob Van Laar, University Medical Centre, Utrecht, the Netherlands

**Aim:** To provide the delegates with an overview of international challenges in the context of global burden of disease

**Outcome 1:** Delegates will be able to identify global developments that affect musculoskeletal health care on a local, national and international level

**Outcome 2:** Delegates will have a better understanding of health disparities in the care of patients with musculoskeletal conditions

**Outcome 3:** Delegates will appreciate the role of the workforce in delivering optimal care

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Making musculoskeletal conditions a global health priority: the need for evidence</td>
<td>Prof Anthony Woolf, Royal Cornwall Hospital, Truro</td>
</tr>
<tr>
<td>09.30</td>
<td>Differences in health across countries: inequalities or inequities?</td>
<td>Dr Annelies Boonen, Maastricht University Medical Center and Caphri Research School, Maastricht, the Netherlands</td>
</tr>
<tr>
<td>10.00</td>
<td>Developing the healthcare workforce to meet the global needs of musculoskeletal conditions</td>
<td>Prof Kristina Akesson, Skane University Hospital, Mali, Sweden</td>
</tr>
</tbody>
</table>

### Time to get moving on increasing physical activity in adults with osteoarthritis

**Chairs:** Dr Kathryn Martin, University of Aberdeen, Aberdeen and Prof Terence O’Neill, University of Manchester, Manchester

**Aim:** To educate the audience on the importance of increasing physical activity in middle-aged adults and older adults with osteoarthritis

**Outcome 1:** Attendees will learn who is physically active, who is not and what research says about the importance of physical activity to improve health outcomes in adults with osteoarthritis

**Outcome 2:** Attendees will learn the evidence on how behavioural interventions can increase physical activity levels in populations of older adults with arthritis

**Outcome 3:** Attendees will learn about a current national campaign to increase physical activity and strategies to raise the issue of physical activity in a clinical setting

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>09.00</td>
<td>Physical activity: epidemiology and its role in improving health in adults with osteoarthritis</td>
<td>Prof Mike Hurley, St George’s University of London, London</td>
</tr>
<tr>
<td>09.30</td>
<td>Increasing physical activity through behavioural intervention in an older population with arthritis</td>
<td>Dr John McBeth, Keele University, Keele</td>
</tr>
<tr>
<td>10.00</td>
<td>Community-based management of osteoarthritis</td>
<td>Dr Nicola Walsh, University of the West of England, Bristol</td>
</tr>
</tbody>
</table>
09.00 – 10.30

Room 4

**Education oral abstracts**

**Chairs:** Dr Inam Haq, Brighton and Sussex Medical School, Brighton and Prof Andrew Hassell, Keele University, Keele

**09.00**

*A national survey of nurse training: confidence and competence for educating patients commencing methotrexate education therapy*

Mrs Sandra Robinson, Northumbria Healthcare NHS Foundation Trust, Tyne and Wear

**09.15**

*Patients awareness of risks and clinical outcomes associated with connective tissue diseases in pregnancy: a cross-sectional study*

Dr Samir Albreshni, University of Manchester, Manchester

**09.30**

*Young people’s decisions about biologic therapies: who influences them and how?*

Ms Ruth Hart, Newcastle University, Newcastle-upon-Tyne

**09.45**

*How do carers of newly-diagnosed patients learn about rheumatoid arthritis? Findings of a serial qualitative study*

Dr Richard Lee, Newcastle University, Newcastle-upon-Tyne

**10.00**

*A multi-centre study showing the utility and flexibility of virtual patients (VPS) to teach musculoskeletal medicine*

Dr James Bateman, University Hospitals Birmingham NHS Trust, Birmingham

**10.15**

*Educating people about osteomalacia: development and evaluation of a multi-language interactive tool*

Mrs Sandra Robinson, Northumbria Healthcare NHS Foundation Trust, Tyne and Wear

---

**09.00 – 10.30 British Health Professionals in Rheumatology connective tissue disease special interest group**

**Chair:** Ms Sue Brown, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath

**Aim:** To be updated on inflammatory myopathies

**Outcome 1:** To develop an understanding about the inflammatory myopathies, including diagnosis and treatment options

**Outcome 2:** To discuss and consider the significance and importance of auto-antibody screening in inflammatory myopathies, and their relevance in clinical practice

**Outcome 3:** To consider the importance of education and information for the individual diagnosed with polymyositis and dermatomyositis gain a knowledge about physiotherapy assessments and interventions and their value in inflammatory myopathies

**09.00**

*Diagnosing and treating polymyositis and dermatomyositis*

Dr Harsha Gunawardena, North Bristol NHS Trust, Bristol

**09.30**

*Auto-antibodies in inflammatory muscle disease, their significance and relevance in clinical practice*

Dr Zoe Betteridge, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath

**10.00**

*Educating and supporting people with active inflammatory myopathies*

Ms Sue Brown, Royal National Hospital for Rheumatic Diseases NHS Foundation Trust, Bath
### Osteoporosis special interest group

**Room 12**

**Aim:** To provide general rheumatologists and trainees with an update about osteoporosis

**Outcome 1:** To inform the audience about the evidence for an association between atypical fractures and bisphosphonates

**Outcome 2:** To increase knowledge on how FRAX can be modified to make it more specific for individual patients

**Outcome 3:** To provide expert advice on common clinical conundrums in osteoporosis

**09.00**

**Debate: this house believes the ticking time bomb of atypical hip fractures caused by bisphosphonates is about to explode**

Dr Emma Clark, Southmead Hospital, Bristol and Dr Mike Stone, Cardiff University and University Hospital Llandough, Cardiff

**09.30**

**PIMP my FRAX/QFracture: how to modify FRAX/QFracture to better fit your patient’s clinical situation**

Prof Eugene McCloskey, Northern General Hospital, Sheffield

**10.00**

**Clinical conundrums: Q&A session with questions supplied by the audience via Twitter**

Dr Ashok Bhalla, Royal National Hospital for Rheumatic Diseases, Bath; Dr Emma Clark, Southmead Hospital, Bristol, and Dr Mike Stone, Cardiff University and University Hospital Llandough, Cardiff

---

### 10.30 – 11.30 Exhibition | Tea and coffee

Exhibition hall

Please see exhibition floor plan on page 89 for catering points.

### 10.30 – 11.30 Poster viewing categories

Exhibition hall

- 1–32 Case reports
- 33–45 Epidemiology
- 46–60 Health services research economics and outcomes research
- 61–75 Primary care
- 76–79 Rheumatoid arthritis: pathogenesis and animal models
- 80–110 Rheumatoid arthritis: treatment
- 111–116 Rheumatoid arthritis: clinical features
- 117–122 Rheumatoid arthritis: comorbidities
- 123–124 Miscellaneous rheumatic diseases
Don’t miss our ever popular poster tours, where small groups are led by experts around carefully selected posters for a Q&A with the poster presenters. Each expert will lead conference participants through a group of approximately 10 posters, allowing presenters to share their research in an interactive format.

Sign up for the poster tours at the poster desk in the exhibition hall. Tours are limited to 15 participants.

<table>
<thead>
<tr>
<th>10.30 - 11.30</th>
<th>Case reports poster tour</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Exhibition hall</strong></td>
<td><strong>Poster tour leaders:</strong> Dr Elizabeth Price, Great Western Hospital, Swindon and Dr Nick Shenker, Cambridge University Hospitals, Cambridge</td>
</tr>
<tr>
<td><strong>02</strong></td>
<td><strong>A curious case of hiccoughs: unusual presentation of eosinophilic granulomatosis with polyangiitis</strong>&lt;br&gt;Dr Maria Wray, South East Health and Social Care Trust, Belfast</td>
</tr>
<tr>
<td><strong>05</strong></td>
<td><strong>A case of refractory anti-synthetase syndrome responding to tacrolimus</strong>&lt;br&gt;Dr Laura Newton, NHS Manchester</td>
</tr>
<tr>
<td><strong>08</strong></td>
<td><strong>Pseudogout of the temporomandibular joint: a case report and literature review</strong>&lt;br&gt;Dr Manish Patel, Watford General Hospital, Watford</td>
</tr>
<tr>
<td><strong>11</strong></td>
<td><strong>A case of amyloid angiopathy mimicking giant cell arteritis</strong>&lt;br&gt;Dr Jasroop Chana, Stoke Mandeville Hospital, Aylesbury</td>
</tr>
<tr>
<td><strong>12</strong></td>
<td><strong>Tocilizumab-induced lupus with renal involvement in a patient with seropositive rheumatoid arthritis</strong>&lt;br&gt;Dr Erin Vermaak, Royal National Hospital for Rheumatic Diseases, Bath</td>
</tr>
<tr>
<td><strong>16</strong></td>
<td><strong>Do you recognise this syndrome?</strong>&lt;br&gt;Dr Jyoti Bakshi, Bucks NHS Trust, Bucks</td>
</tr>
<tr>
<td><strong>20</strong></td>
<td><strong>Cocaine: the vasculitits mimic!</strong>&lt;br&gt;Dr Aikaterini Panopoulou, Heatherwood and Wexham Park Hospital NHS Trust, Slough</td>
</tr>
<tr>
<td><strong>23</strong></td>
<td><strong>Limbic encephalitis associated with Behcet’s disease</strong>&lt;br&gt;Dr Nehal Narayan, Russell's Hall Hospital, Dudley</td>
</tr>
<tr>
<td><strong>30</strong></td>
<td><strong>Idiopathic spinal subarachnoid haemorrhage in a patient with fibromyalgia and primary Sjögren’s syndrome</strong>&lt;br&gt;Dr Jessica Gunn, Royal Berkshire Hospital, Reading</td>
</tr>
<tr>
<td><strong>32</strong></td>
<td><strong>Self-aspiration of a knee joint, in the youtube generation</strong>&lt;br&gt;Dr Esther Chan, Sunderland Royal Hospital, Sunderland</td>
</tr>
<tr>
<td>62</td>
<td>What are the characteristics of musculoskeletal primary care consultations in patients aged 45 and over?</td>
</tr>
<tr>
<td>----</td>
<td>------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td></td>
<td>Miss Sweta Parida, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>63</th>
<th>A pain in the neck: the association between chronic health conditions and frequent consultation in primary care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Jonathan Broad, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>64</th>
<th>Practitioner empathy and musculoskeletal patients' outcomes in primary care</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Eliot L. Rees, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>67</th>
<th>Diagnosis and treatment of gout in primary care: a qualitative study of patient experience</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Jane Richardson, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>68</th>
<th>Are the BSR and BHPR guidelines for the management of polymyalgia rheumatica followed in primary care?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr William Cooke, North Middlesex University Hospital, London</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>71</th>
<th>Managing osteoarthritis in general practice: can training enhance the osteoarthritis consultation?</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Mark Porcheret, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>74</th>
<th>Uptake of the nice osteoarthritis core treatments in community dwelling older adults with a self-reported primary care consultation for joint pain</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Emma Healey, Keele University, Keele</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>75</th>
<th>How do GPs explain chronic knee pain in older adults? Preliminary results from a national pilot GP questionnaire survey</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dr Elizabeth Cottrell, Keele University, Keele</td>
</tr>
</tbody>
</table>
Tuesday 29 April

**Poster tours**

**10.30 – 11.30**

**Exhibition hall**

**Rheumatoid arthritis poster tour**

**Poster tour leader:** Prof David L. Scott, King’s College London, London

<table>
<thead>
<tr>
<th>Number</th>
<th>Title</th>
<th>Presenter</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>26</td>
<td>Rheumatoid arthritis related interstitial lung disease - association between steroid therapy and survival</td>
<td>Dr Clive Kelly</td>
<td>Queen Elizabeth Hospital, Gateshead</td>
</tr>
<tr>
<td>76</td>
<td>Immune complex retention by synovial fibroblasts in rheumatoid arthritis</td>
<td>Miss Alia Al-Mousawi</td>
<td>William Harvey Research Institute, London</td>
</tr>
<tr>
<td>79</td>
<td>Investigation of the role of histone deacetylases in rheumatoid arthritis synovial fibroblasts</td>
<td>Miss Sarah Hawtree</td>
<td>University of Sheffield, Sheffield</td>
</tr>
<tr>
<td>89</td>
<td>Influence of immunogenicity on the efficacy of long-term treatment of rheumatoid arthritis with adalimumab: a UK based prospective study</td>
<td>Dr Meghna Jani</td>
<td>University of Manchester, Manchester</td>
</tr>
<tr>
<td>92</td>
<td>Differences in the efficacy and tolerability of anti-TNF therapies in patients with rheumatoid arthritis from diverse ethnic groups</td>
<td>Dr Kanta Kumar</td>
<td>University of Birmingham, Birmingham</td>
</tr>
<tr>
<td>99</td>
<td>Identifying characteristics of rheumatoid arthritis patients able to reduce anti-TNF using a real-life strategy combining clinical and ultrasound assessment</td>
<td>Dr Jonathan Marks</td>
<td>University Hospital Southampton NHS Foundation Trust, Southampton</td>
</tr>
<tr>
<td>101</td>
<td>Synovial ectopic lymphoneogenesis predicts primary clinical response to certolizumab pegol in patients with rheumatoid arthritis</td>
<td>Dr Maria Di Cicco</td>
<td>Queen Mary University of London, London</td>
</tr>
<tr>
<td>107</td>
<td>Synovial B-cells predict response/resistance to rituximab therapy in rheumatoid arthritis: preliminary results from a pilot study</td>
<td>Dr Arti Mahto</td>
<td>Queen Mary University, Barts and the London School of Medicine and Dentistry, London</td>
</tr>
<tr>
<td>111</td>
<td>Development of a minimum core dataset for observational cohort studies in rheumatoid arthritis</td>
<td>Dr Elena Nikiphorou</td>
<td>University College London, London</td>
</tr>
</tbody>
</table>
Tuesday 29 April

10.30 – 11.00

Innovation theatre: Roche Products Ltd and Chugai Pharma UK Ltd
Exhibition hall

Examining non-adherence in rheumatoid arthritis: what interventions benefit patient outcomes?
Speaker: Professor John Weinman, King’s College London, London

11.30 – 13.00

What do we mean by a flare of rheumatoid arthritis?
Hall 1A

Aim: To provide clinicians with an overview of the different ways in which patients and professionals understand flare
Outcome 1: Delegates will have a better understanding of what patients with rheumatoid arthritis mean by the term ‘flare’
Outcome 2: Delegates will be aware of how patients’ and professionals’ differing definitions can still lead to consensus
Outcome 3: Delegates will understand the complex and delicate balance of a fluctuating, flaring condition

11.30
Patient experiences and definitions of flare (duvet and chocolate days)
Prof Sarah Hewlett, University of the West of England, Bristol

12.00
Obtaining patient and professional consensus on flare, and testing its accuracy in drug trials
Prof Ernest Choy, Cardiff University, Cardiff

12.30
Life as fluctuating balance: flare tipping points, inflammatory and avalanche flares
Dr Caroline Flurey, University of the West of England, Bristol

11.30 – 13.00

Biosimilars in perspective
Room 3

Aim: To bring delegates up to date on the impact that the imminent introduction of biosimilars will have on clinical practice, and the implications for patients and prescribers
Outcome 1: Gain understanding of the biology and manufacture of biosimilars
Outcome 2: Gain understanding of the regulatory framework in which biosimilars will be licensed for use
Outcome 3: Raise awareness of the risks and benefits of using biosimilars in clinical practice

11.30
The science of biosimilars
Prof John Isaacs, Newcastle University, Newcastle-upon-Tyne

11.50
The commercial marketplace
Mr Peter Stenico, Sandoz International GmbH, Holzkirchen, Germany

12.10
Biosimilars in perspective: regulation
Dr Bill Richardson, NDA Group, London

12.30
The place of biosimilars in clinical practice
Prof Peter Taylor, University of Oxford, Oxford

12.50
Discussion
11.30 – 13.00 Primary care oral abstracts

Chair: Dr Karen Walker-Bone, Southampton General Hospital, Southampton

11.30 The primary care osteoarthritis consultation: dissonance and consonance
Dr Zoe Paskins, Keele University, Keele

11.45 A negative rheumatoid factor in primary care delays referral of patients with rheumatoid arthritis
Dr Anne Miller, Nuffield Orthopaedic Centre, Oxford

12.00 Impact of quality outcome framework indicators for rheumatoid arthritis and cardiovascular risk on three separate GP practices
Dr Matthew Wiggins, Lancashire Care NHS Foundation Trust, Preston

12.15 Prevalence and associations of posterior heel pain in the general population: an epidemiological study
Dr Benjamin Chatterton, Keele University, Keele

12.30 Consultation patterns following treatment at a musculoskeletal clinical assessment and treatment service (CATS): a twelve-month prospective study
Dr Ed Roddy, Keele University, Keele

12.45 The prevalence of axial spondyloarthritis in the UK: a cross sectional cohort study in a primary care population
Dr Louise Hamilton, Norfolk and Norwich University Hospital, Norwich

11.30 – 13.00 Thirty years of the British Society for Rheumatology

Join us to celebrate thirty years of the British Society for Rheumatology (BSR), an organisation that is going from strength to strength. We will take a look back at the transformations in rheumatology care over the three decades, and look forward to the further advances that are already within our reach.

Chairs: Dr Deborah Bax, University of Sheffield, Sheffield and Prof David G. I. Scott, Norfolk and Norwich University Hospital, Norwich

Aim: To cover the history and main achievements of the BSR over the last thirty years
Outcome 1: Delegates will understand the importance and relevance of the BSR
Outcome 2: Delegates will understand the importance of BSR Biologics Register (BSRBR)
Outcome 3: Delegates will understand the importance of both BSR and BSRBR to the future of our speciality

11.30 The British Society for Rheumatology: origin of the species
Prof George Nuki, University of Edinburgh, Edinburgh

11.45 The British Society for Rheumatology: evolution of the species
Prof David Isenberg, University College London, London

12.15 The British Society for Rheumatology Biologics Register: origins and aims
Prof Alan Silman, Arthritis Research UK

12.30 The British Society for Rheumatology Biologics Register: impact
Dr Kimme Hyrich, University of Manchester, Manchester

12.45 The British Society for Rheumatology: future of the species
Prof Simon Bowman, Queen Elizabeth Hospital, Birmingham
Patients’ and carers’ direct involvement in musculoskeletal research and service delivery: what are the benefits and challenges?

Chairs: Dr Lynne Goodacre, NHS Research and Development North West and Dr Claire Jinks, Keele University, Keele

Aim: To explore the impact of differing models of public and patient involvement (PPI) strategies on service development and research within contemporary rheumatology healthcare

Outcome 1: Attendees will understand the current evidence base and the requirements of charities and public funding bodies for PPI
Outcome 2: Attendees will recognise the scope and opportunity for public and patient involvement within musculoskeletal research
Outcome 3: Attendees will recognise how PPI can shape service delivery in secondary care for patients with inflammatory arthritis and will appreciate the relevance of public and patient involvement from a perspective of a PPI representative

Patient involvement in research: what is the evidence and the scope of public and patient involvement in musculoskeletal research?
Dr Jo Adams, University of Southampton, Southampton and Dr Heidi Lempp, King’s College London, London

How can patients effectively shape rheumatology service delivery in secondary care?
Ms Denise Pope, University Hospitals Bristol NHS Foundation Trust, Bristol

Experiences of being a public and patient involvement representative for clinical rheumatology research
Dr Ruth Williams, Wells Park Practice, London

Osteoarthritis and bone oral abstracts

Chairs: Dr Emma Clark, Southmead Hospital, Bristol and Prof Ian Clark, University of East Anglia, Norwich

Impact of components of the metabolic syndrome on progression of knee osteoarthritis in the sekoia study
Dr Mark Edwards, University of Southampton, Southampton

Cost-effectiveness of total hip replacements: a comprehensive model
Mr Rafael Pinedo-Villanueva, University of Oxford, Oxford

The triad of osteophytes, enthesophytes and increased bone mass may help to define a ‘bone-forming’ sub-type of osteoarthritis
Dr Sarah Hardcastle, University of Bristol, Bristol

Can long-term bisphosphonate and drug holiday review in primary care be performed by a clinical pharmacist?
Ms Louise Maguire, Freeman Hospital, Newcastle-upon-Tyne

Bone microarchitecture assessed by high resolution peripheral quantitative computed tomography is associated with fracture in older men and women
Dr Mark Edwards, University of Southampton, Southampton

Dual-energy X-ray absorptiometry (DXA) measures of bone mass in mother, father and offspring: results from the Southampton women’s survey
Dr Christopher Holroyd, University of Southampton, Southampton
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.30</td>
<td><strong>Myositis special interest group</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room 12</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Dr Hector Chinoy, University of Manchester, Manchester and Dr Patrick Gordon,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>King’s College Hospital, London</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Aim:</strong> To provide an update on current issues in myositis and upcoming research/clinical</td>
<td></td>
</tr>
<tr>
<td></td>
<td>activities relevant to the clinical management of myositis</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 1:</strong> To provide an update on current clinical trial activity in myositis</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 2:</strong> To raise awareness of how to diagnosis, manage and treat newly defined</td>
<td></td>
</tr>
<tr>
<td></td>
<td>serotypes in the inflammatory myopathy spectrum</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 3:</strong> To discuss a number of challenging myositis cases and to enter a discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td>about best practice in the treatment of myositis</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Myositis clinical trials update 2014</strong></td>
<td>Dr Hector Chinoy, University of Manchester, Manchester</td>
</tr>
<tr>
<td>12.00</td>
<td><strong>Challenging myositis cases for discussion</strong></td>
<td>Dr Patrick Kiely, St George’s Hospital, London</td>
</tr>
<tr>
<td>12.30</td>
<td><strong>Myositis autoantibodies in clinical practice</strong></td>
<td>Prof David Isenberg, University College London, London</td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Polymyalgia rheumatica and giant cell arteritis special interest group</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Room 11A</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Chair:</strong> Prof Bhaskar Dasgupta, Southend University Hospital, Southend-on-Sea</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Aim:</strong> To make attendees aware of recent service pathways, classification criteria,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>guidelines and clinical trials for polymyalgia rheumatica and giant cell arteritis</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 1:</strong> To learn about the implementation of the fast track pathway for giant cell</td>
<td></td>
</tr>
<tr>
<td></td>
<td>arteritis; improved outcomes including the reduction of sight loss with cost effectiveness</td>
<td></td>
</tr>
<tr>
<td></td>
<td>analysis of the pathway. There will also be discussion regarding resources required for</td>
<td></td>
</tr>
<tr>
<td></td>
<td>‘roll out’ of the pathway.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 2:</strong> To learn about the EULAR ACR Guidelines for polymyalgia rheumatica; the</td>
<td></td>
</tr>
<tr>
<td></td>
<td>literature review and appraisal of the evidence including the literature review of imaging</td>
<td></td>
</tr>
<tr>
<td></td>
<td>indications for polymyalgia rheumatica and the draft ACR EULAR recommendations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Outcome 3:</strong> To learn about a therapy update from clinical trials that are ongoing or</td>
<td></td>
</tr>
<tr>
<td></td>
<td>in setup for polymyalgia rheumatica and giant cell arteritis</td>
<td></td>
</tr>
<tr>
<td>11.30</td>
<td><strong>Fast track giant cell arteritis pathway</strong></td>
<td>Prof Bhaskar Dasgupta, Southend University Hospital, Southend-on-Sea</td>
</tr>
<tr>
<td>11.50</td>
<td><strong>Neutrophils in giant cell arteritis and polymyalgia rheumatica</strong></td>
<td>Prof Mauro Perretti, Queen Mary's University, London</td>
</tr>
<tr>
<td>12.10</td>
<td><strong>EULAR ACR polymyalgia rheumatica guidelines</strong></td>
<td>Prof Bhaskar Dasgupta, Southend University Hospital, Southend-on-Sea</td>
</tr>
<tr>
<td>12.30</td>
<td><strong>Clinical trials polymyalgia rheumatica and giant cell arteritis</strong></td>
<td>Dr Sarah Mackie, St James University Hospital, Leeds</td>
</tr>
<tr>
<td>12.50</td>
<td><strong>Lodotra in giant cell arteritis</strong></td>
<td>Dr Charles Raine, Southend University Hospital, Southend-on-Sea</td>
</tr>
</tbody>
</table>

**Exhibition | Lunch**

Exhibition hall: Please see exhibition floor plan on page 89 for catering points.
### 13.00 – 13.30
**Innovation theatre: AbbVie Ltd**

**Exhibition hall**

**Ultrasound – The future of standard RA assessment**

Chair: Professor Paul Emery, University of Leeds, Leeds

Speakers: Dr Cristina Estrach, University Hospital Aintree NHS Foundation Trust, Liverpool; Mrs Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole and Dr Richard Wakefield, University of Leeds, Leeds

### 13.45 – 14.15
**Innovation theatre: AbbVie Ltd**

**Exhibition hall**

**Ultrasound – The future of standard RA assessment**

Chair: Professor Paul Emery, University of Leeds, Leeds

Speakers: Dr Cristina Estrach, University Hospital Aintree NHS Foundation Trust, Liverpool; Mrs Tricia Cornell, Poole Hospital NHS Foundation Trust, Poole and Dr Richard Wakefield, University of Leeds, Leeds

### 13.00 – 13.15
**PhD and postgraduate student network**

**Room 11B**

**Chair:** Dr Caroline Flurey, University of the West of England, Bristol

**Aim:** To facilitate career progression and to facilitate networking

**Outcome 1:** Attendees will understand post-doctoral career routes

**Outcome 2:** Attendees will understand key points for applications

**Outcome 3:** Attendees will have discussed their careers with a senior academic

**13.00**

**What can I do after my PhD? Planning for your future career**

Dr Ross Wilkie, Keele University, Keele

**13.15**

**How do I write a grant or fellowship application?**

Prof Sarah Hewlett, University of the West of England, Bristol

**13.25**

**Discussions with senior academics to discuss your own plans and top tips for getting there**

Dr Caroline Flurey, University of the West of England, Bristol; Prof Sarah Hewlett, University of the West of England, Bristol and Dr Ross Wilkie, Keele University, Keele

### 13.00 – 14.15
**The British Society for Rheumatology Biologics Registers open meeting**

**Room 3**

**Aim:** To inform all those wanting to understand the implications of registers’ research for their practice. Open to all with an interest in the Biologics Registers, whether as a contributor of patient data or as a researcher interested in accessing the data

**Outcome 1:** Key clinical messages and latest research findings from the rheumatoid arthritis register

**Outcome 2:** Update on recruitment to the ankylosing spondylitis (AS) and rheumatoid arthritis (RA) registers

**Outcome 3:** Update on ongoing research and opportunities to analyse the data

Speakers will include Dr Kimme Hyrich, University of Manchester, Manchester; Dr Gareth Jones, University of Aberdeen, Aberdeen and Prof Alex MacGregor, University of East Anglia, Norwich
### Keynote session | Networking

#### Tuesday 29 April

#### 14.15 – 17.45

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14.15</td>
<td>Keynote address</td>
<td>Hall 1</td>
</tr>
<tr>
<td>14.35</td>
<td>Michael Mason prize winner: Serendipitous hoarding - the story of the Hertfordshire ledgers</td>
<td>Hall 1</td>
</tr>
<tr>
<td>14.55</td>
<td>Garrod prize winner: targeting toll-like receptors in rheumatoid arthritis</td>
<td>Hall 1</td>
</tr>
<tr>
<td>15.15</td>
<td>Delays between the onset of symptoms and first rheumatology consultation in patients with rheumatoid arthritis: a national survey</td>
<td>Hall 1</td>
</tr>
<tr>
<td>15.35</td>
<td>Incidence and severity of myocardial infarction in subjects receiving anti-tumour necrosis factor drugs for rheumatoid arthritis: results from linking the British Society for Rheumatology Biologics Register for rheumatoid arthritis and myocardial ischaemia national audit project</td>
<td>Hall 1</td>
</tr>
<tr>
<td>15.55</td>
<td>Methotrexate: a novel mechanism for vasculoprotection in chronic systemic inflammation</td>
<td>Hall 1</td>
</tr>
</tbody>
</table>

#### 16.15 – 16.45

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.15</td>
<td>Exhibition</td>
<td>Exhibition hall</td>
</tr>
</tbody>
</table>

Please see exhibition floor plan on page 89 for catering points.

#### 16.45 – 17.45

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.45</td>
<td>Heberden Round</td>
<td>Hall 1</td>
</tr>
</tbody>
</table>

Chair: Dr Chris Deighton, President of the British Society of Rheumatology

The Heberden Round was initiated in 1948 to acknowledge the work of an individual’s outstanding contribution to clinical rheumatology.

#### From Bark to B Cells

Dr Richard Watts, Ipswich Hospital NHS Trust, Ipswich
**Industry supported symposium: Bristol-Myers Squibb**

**Treatment decisions in RA: Can understanding mode of action help us make a better treatment decision?**

Chair: Professor Robert Moots, University of Liverpool, UK

**Aim:**

The National Institute for Health and Clinical Effectiveness (NICE) has approved a number of biologic agents for the treatment of rheumatoid arthritis (RA) in the UK, providing treatment options with a range of different mechanisms of action (MoA). This session aims to challenge the way in which health professionals think when choosing which class of biologic to use following failure of conventional DMARDS, and explores the potential impact of different modes of action on treatment outcomes.

**Outcome 1:** The audience will be able to better understand the MoAs of different classes of biologics available for RA, and how this insight can help them to individualize treatment.

**Outcome 2:** The audience will be able to better understand the latest evidence from drug trials and observational studies of different classes of biologic in RA.

**Outcome 3:** The audience will be able to recognize the impact of choosing the most appropriate, effective treatment in order to deliver tight control and improve long-term patient outcomes in RA.

---

**17.45–17.50**

**Introduction: The heterogeneous nature of RA**

Professor Robert Moots, University of Liverpool, UK

**17.50–18.00**

**Cytokine inhibition: direct regulation of proinflammatory signals**

Professor Ernest Choy, Cardiff University, UK

- Intro to driving forces in the pathogenesis of RA
- Role of cytokines within inflammatory response/RA pathogenesis

**18.00–18.10**

**T-cell co-stimulation blockade: the potential to impact early pathophysiology**

Professor John Isaacs, Newcastle University, UK

- Potential for abatacept to alter the course of RA disease by working upstream, compared with other biologic DMARDs

**18.10–18.20**

**Discussion**

Chair and speakers

**18.20–18.25**

**Can mode of action, combined with clinical evidence, help us decide which biologic to use on a patient-by-patient basis?**

Professor Robert Moots, University of Liverpool, UK

**18.25–18.45**

**Understanding the clinical impact of cytokine blockade**

Professor Ernest Choy, Cardiff University, UK

- Clinical data in DMARD-IR patients
  - Anti-TNFs
  - Tocilizumab

**18.45–19.05**

**Understanding the clinical impact of T-cell modulation**

Professor John Isaacs, Newcastle University, UK

- Clinical data in patients with inadequate response to MTX, DMARDS, or anti-TNFs
  - Abatacept

**19.05–19.15**

**Discussion**

Chair and speakers
TREATMENT DECISIONS IN RA: Can understanding mode of action help us make a better treatment decision?

Tuesday, 29 April 2014, 17:45-19:15, Room 11B, ACC, Kings Dock, Liverpool, UK

Chair: Professor Robert Moots, University of Liverpool, UK

Introduction: The heterogeneous nature of RA

Cytokine inhibition: direct regulation of proinflammatory signals
Professor Ernest Choy, Cardiff University, UK

T-cell co-stimulation blockade: the potential to impact early pathophysiology
Professor John Isaacs, Newcastle University, UK

Discussion Chair & speakers

Organised and funded by Bristol-Myers Squibb
Tuesday 29 April  Industry supported symposium

**17.45 – 19.45**

**Industry supported symposium: MSD**

**Spondyloarthropathies: today and tomorrow**
Chair: Prof David Marshall, Inverclyde Royal Hospital, Greenock

**Aim:** To provide delegates with an overview on management of spondyloarthropathies past and present

**Outcome 1:** An update on the current and future management of psoriatic arthritis

**Outcome 2:** An update on the current and future management of ankylosing spondylitis

**Outcome 3:** An update on the current and future science of cytokines in spondyloarthropathy

**17.45**
**Refreshments**

**18.15**
**Welcome and introduction**
Prof David Marshall, Inverclyde Royal Hospital, Greenock

**18.25**
**Psoriatic arthritis: today and tomorrow**
Prof Douglas Veale, St. Vincent’s Hospital, Dublin

**18.45**
**Ankylosing spondylitis: yesterday, today and tomorrow**
Dr Karl Gaffney, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich

**19.05**
**Cytokine biology of spondyloarthropathies: today and tomorrow**
Dr Jonathan Sherlock, University of Birmingham, Birmingham

**19.25**
**Question and answers**

**19.40**
**Summary**

**19.45 – 21.00**

**30th Anniversary dinner and Presidents’ reception**

Join the Presidents of both the British Society for Rheumatology and British Health Professionals in Rheumatology for an exciting circus-themed event at Circo on the beautiful Albert Dock.

The Presidents’ reception is free to attend for all delegates and will include entertainment as well as a selection of celebratory drinks and canapés. In addition to helping us celebrate 30 years of the British Society for Rheumatology, the reception will provide the perfect backdrop to network with existing colleagues.

The conference dinner promises to be a highlight and is almost sold out so enquire at registration if you would like to attend.

**Circo**
Albert Dock

---

**BSR**
stronger together **BHPR**
A MSD Scientific Symposium
Tuesday, April 29th 2014
17:45 - 19:45
ROOM 3A
The Arena Convention Centre, King’s Dock, Waterfront, Liverpool. L3 4FP

CHAIR: Professor David Marshall
Hon. Clinical Associate Professor, Consultant Rheumatologist & Physician
Inverclyde Royal Hospital, Greenock

17:45 Refreshments
18:15 Welcome & Introduction
Prof David Marshall, Inverclyde Royal Hospital, Greenock
18:25 Psoriatic Arthritis - Today and Tomorrow
Prof Douglas Veale, St. Vincent’s Hospital, Dublin
18:45 Ankylosing Spondylitis - Yesterday, Today and Tomorrow
Dr Karl Gaffney, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
19:05 Cytokine biology of spondyloarthropathies - Today and Tomorrow
Dr Jonathan Sherlock, University of Birmingham, Birmingham
19:25 Question and answer session
19:40 Summary

Aim: To provide delegates with an overview on management of spondyloarthropathies past and present

Outcome 1: An update on the current and future management of PsA
Outcome 2: An update on the current and future management of ankylosing spondylitis
Outcome 3: An update on the current and future science of cytokines in spondyloarthropathy